News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,826 Results
Type
Article (14910)
Company Profile (299)
Press Release (266611)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79839)
Career Advice (163)
Deals (13337)
Drug Delivery (39)
Drug Development (50705)
Employer Resources (31)
FDA (5838)
Job Trends (5169)
News (145089)
Policy (10072)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (19)
Adcomms (14)
Allergies (85)
Alliances (21761)
ALS (126)
Alzheimer's disease (1035)
Antibody-drug conjugate (ADC) (243)
Approvals (6033)
Artificial intelligence (265)
Autoimmune disease (118)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (46)
Breast cancer (347)
Cancer (3158)
Cardiovascular disease (239)
Career advice (148)
Career pathing (8)
CAR-T (222)
CDC (5)
Cell therapy (573)
Cervical cancer (14)
Clinical research (43719)
Collaboration (1163)
Company closure (2)
Compensation (602)
Complete response letters (41)
COVID-19 (1101)
CRISPR (86)
C-suite (564)
Cystic fibrosis (112)
Data (4354)
Denatured (15)
Depression (93)
Diabetes (256)
Diagnostics (1382)
Digital health (12)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (195)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (218)
Earnings (31666)
Editorial (26)
Employer branding (4)
Employer resources (29)
Events (51704)
Executive appointments (628)
FDA (7603)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (10)
Frontotemporal dementia (22)
Funding (991)
Gene editing (183)
Generative AI (22)
Gene therapy (495)
GLP-1 (507)
Government (1149)
Grass and pollen (3)
Guidances (166)
Healthcare (6612)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (194)
Immuno-oncology (43)
Indications (70)
Infectious disease (1210)
Inflammatory bowel disease (157)
Inflation Reduction Act (10)
Influenza (40)
Intellectual property (169)
Interviews (18)
IPO (7346)
IRA (13)
Job creations (867)
Job search strategy (130)
JPM (40)
Kidney cancer (9)
Labor market (23)
Layoffs (243)
Leadership (10)
Legal (1401)
Liver cancer (41)
Longevity (11)
Lung cancer (424)
Lymphoma (251)
Machine learning (24)
Management (7)
Manufacturing (379)
MASH (131)
Medical device (2664)
Medtech (2673)
Mergers & acquisitions (6623)
Metabolic disorders (732)
Multiple sclerosis (104)
NASH (13)
Neurodegenerative disease (233)
Neuropsychiatric disorders (70)
Neuroscience (1963)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (866)
Now hiring (31)
Obesity (333)
Opinion (125)
Ovarian cancer (132)
Pain (102)
Pancreatic cancer (164)
Parkinson's disease (232)
Partnered (12)
Patents (305)
Patient recruitment (343)
Peanut (44)
People (26683)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15492)
Phase 2 (20314)
Phase 3 (12828)
Pipeline (3340)
Policy (91)
Postmarket research (853)
Preclinical (6540)
Press Release (30)
Prostate cancer (147)
Psychedelics (50)
Radiopharmaceuticals (239)
Rare diseases (660)
Real estate (1448)
Recruiting (12)
Regulatory (9917)
Reports (19)
Research institute (972)
Resumes & cover letters (19)
Rett syndrome (24)
RNA editing (21)
RSV (17)
Schizophrenia (124)
Series A (184)
Series B (140)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2008)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (339)
Venture capital (69)
Weight loss (174)
Women's health (26)
Worklife (2)
Date
Today (70)
Last 7 days (297)
Last 30 days (1150)
Last 365 days (17869)
2026 (1913)
2025 (18098)
2024 (20543)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11739)
2017 (13746)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18269)
Australia (3114)
California (7128)
Canada (1852)
China (781)
Colorado (249)
Connecticut (255)
Delaware (236)
Europe (39205)
Florida (910)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (396)
India (36)
Indiana (162)
Iowa (8)
Japan (227)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (738)
Massachusetts (5622)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (33)
New Hampshire (21)
New Jersey (1657)
New Mexico (13)
New York (1773)
North Carolina (836)
North Dakota (6)
Northern California (3508)
Ohio (179)
Oklahoma (11)
Oregon (24)
Pennsylvania (1287)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2826)
Tennessee (40)
Texas (918)
United States (23498)
Utah (97)
Virginia (137)
Washington D.C. (37)
Washington State (593)
West Virginia (1)
Wisconsin (46)
281,826 Results for "bluerock therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease
October 7, 2025
·
8 min read
Press Releases
BlueRock Therapeutics announces first patient receives investigational therapy in Phase 1/2a clinical trial of OpCT-001 for the treatment of primary photoreceptor diseases
July 8, 2025
·
8 min read
Business
BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics
BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, announced today that it has exercised its option to exclusively license OpCT-001, an induced pluripotent stem cell (iPSC) derived cell therapy candidate for the treatment of primary photoreceptor diseases, from FUJIFILM Cellular Dynamics and Opsis Therapeutics.
January 23, 2024
·
7 min read
Drug Development
BlueRock Therapeutics’ Investigational Cell Therapy Bemdaneprocel for Parkinson’s Disease Shows Positive Data at 24-Months
September 27, 2024
·
10 min read
Business
BioCardia Enters Agreement with BlueRock Therapeutics to Provide Enabling Catheter Biotherapeutic Delivery Product Candidates for BlueRock’s Cell Therapy to Treat Heart Failure
BioCardia ® , Inc. [Nasdaq: BCDA], today announced that it has entered into an agreement with BlueRock Therapeutics LP for the delivery of BlueRock’s cell therapy product candidates for the treatment of heart failure utilizing BioCardia’s minimally invasive biotherapeutic delivery product candidates.
August 24, 2022
·
3 min read
Business
BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery and manufacture of regulatory T cell (Treg) based therapies
BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, and bit.bio, the company coding human cells for novel cures, today announced a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T cells (Tregs) for use in creating therapeutics.
August 3, 2023
·
7 min read
Business
BlueRock Therapeutics to use Rune Labs’ clinical trial platform to better characterize Parkinson’s disease state in cell therapy trials
Rune Labs today announced a partnership with BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned, independently operated subsidiary of Bayer AG.
March 14, 2023
·
4 min read
Drug Development
BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint
Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, announced details of the positive data from the Phase I clinical trial for bemdaneprocel, a stem cell derived investigational therapy for treating Parkinson’s disease.
August 28, 2023
·
9 min read
Press Releases
NeuroEM Therapeutics(R) Appoints Dr. W. Scott Burgin as Chief Medical Officer
February 1, 2026
·
2 min read
Genetown
BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson’s disease clinical trial
BlueRock Therapeutics LP today announced a collaboration with Rune Labs and Emerald Innovations focused on using wearable and invisible contactless digital health technology to improve monitoring and data collection for Parkinson’s disease clinical trials.
March 14, 2023
·
9 min read
1 of 28,183
Next
